Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models.

MLA

Wu, Yinglin, et al. “Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models.” Viruses (1999-4915), vol. 14, no. 12, Dec. 2022, p. 2796. EBSCOhost, https://doi.org/10.3390/v14122796.

APA

Wu, Y., Chen, X., Wang, L., Zhou, X., Liu, Y., Ji, D., Ren, P., Zhou, G. G., & Zhao, J. (2022). Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models. Viruses (1999-4915), 14(12), 2796. https://doi.org/10.3390/v14122796

Chicago

Wu, Yinglin, Xiaoqing Chen, Lei Wang, Xusha Zhou, Yonghong Liu, Dongmei Ji, Peigen Ren, Grace Guoying Zhou, and Jing Zhao. 2022. “Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models.” Viruses (1999-4915) 14 (12): 2796. doi:10.3390/v14122796.